In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...
GSK (NYSE:GSK) said it has started to appeal a recent court ruling in Delaware that allowed tens of thousands of lawsuits to ...
, opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left ...
GSK Plc, Pfizer Inc. and other drugmakers must face trials in state court in Delaware after a judge found the evidence ...
A woman who claimed in a lawsuit that GSK’s discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that ...